Cytosorbents (NASDAQ:CTSO) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note released on Tuesday. The firm issued a hold rating on the medical research company’s stock.

Several other research analysts have also recently weighed in on the stock. HC Wainwright reissued a “neutral” rating and issued a $1.00 price target on shares of Cytosorbents in a report on Monday, November 11th. EF Hutton Acquisition Co. I raised Cytosorbents to a “strong-buy” rating in a report on Monday, July 29th.

Cytosorbents Price Performance

NASDAQ:CTSO opened at $0.91 on Tuesday. The company has a market cap of $49.77 million, a P/E ratio of -2.53 and a beta of 0.56. The firm’s fifty day moving average price is $1.09 and its two-hundred day moving average price is $1.01. Cytosorbents has a one year low of $0.70 and a one year high of $2.15. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CTSO. Sargent Investment Group LLC boosted its stake in shares of Cytosorbents by 13.4% in the third quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock valued at $2,439,000 after buying an additional 192,747 shares during the period. CM Management LLC lifted its position in shares of Cytosorbents by 3.0% during the 2nd quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock valued at $598,000 after acquiring an additional 25,000 shares during the period. Geode Capital Management LLC grew its holdings in shares of Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after purchasing an additional 32,415 shares in the last quarter. Finally, Atomi Financial Group Inc. bought a new position in shares of Cytosorbents in the third quarter worth $51,000. Institutional investors and hedge funds own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.